Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

doi:10.1016/j.annonc.2020.08.2099

Practice Guideline

. 2020 Nov;31(11):1476-1490.

doi: 10.1016/j.annonc.2020.08.2099. Epub 2020 Aug 27.

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Affiliations

¹ Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany; Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.
² Department of Endocrinology, Reference Centre for Rare Adrenal Diseases, Reference Centre for Rare Adrenal Cancers, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France; Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
³ Department of Endocrine Oncology and Nuclear Medicine, Gustave Roussy, Villejuif, France.
⁴ Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
⁵ Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
⁶ Department of Internal Medicine Máxima Medisch Centrum, Eindhoven, The Netherlands; Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands; Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, The Netherlands.
⁷ Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
⁸ Division of Urology, San Luigi Hospital - Orbassano, Turin, Italy; Department of Oncology, University of Turin, Turin, Italy.
⁹ Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Turin, Italy.
¹⁰ Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia, Italy.

PMID: 32861807
DOI: 10.1016/j.annonc.2020.08.2099

Free article

Practice Guideline

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

M Fassnacht et al. Ann Oncol. 2020 Nov.

Free article

. 2020 Nov;31(11):1476-1490.

doi: 10.1016/j.annonc.2020.08.2099. Epub 2020 Aug 27.

Affiliations

¹ Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany; Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.
² Department of Endocrinology, Reference Centre for Rare Adrenal Diseases, Reference Centre for Rare Adrenal Cancers, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France; Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
³ Department of Endocrine Oncology and Nuclear Medicine, Gustave Roussy, Villejuif, France.
⁴ Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
⁵ Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
⁶ Department of Internal Medicine Máxima Medisch Centrum, Eindhoven, The Netherlands; Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands; Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, The Netherlands.
⁷ Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
⁸ Division of Urology, San Luigi Hospital - Orbassano, Turin, Italy; Department of Oncology, University of Turin, Turin, Italy.
⁹ Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Turin, Italy.
¹⁰ Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia, Italy.

PMID: 32861807
DOI: 10.1016/j.annonc.2020.08.2099

Erratum in

Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490].
Fassnacht M, Assie G, Baudin E, Eisenhofer G, Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Fassnacht M, et al. Ann Oncol. 2023 Jul;34(7):631. doi: 10.1016/j.annonc.2022.12.006. Epub 2022 Dec 21. Ann Oncol. 2023. PMID: 36564283 No abstract available.

No abstract available

Keywords: Clinical Practice Guidelines; adrenal cancer; diagnosis; follow-up; treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA, CdlF, GE, FP and Rdk have declared no potential conflicts of interest.

Cited by

Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.
Tőke J, Uhlyarik A, Lohinszky J, Stark J, Huszty G, Micsik T, Borka K, Reismann P, Horányi J, Igaz P, Tóth M. Tőke J, et al. Front Endocrinol (Lausanne). 2022 Sep 29;13:952418. doi: 10.3389/fendo.2022.952418. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36246926 Free PMC article.
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
Calsina B, Piñeiro-Yáñez E, Martínez-Montes ÁM, Caleiras E, Fernández-Sanromán Á, Monteagudo M, Torres-Pérez R, Fustero-Torre C, Pulgarín-Alfaro M, Gil E, Letón R, Jiménez S, García-Martín S, Martin MC, Roldán-Romero JM, Lanillos J, Mellid S, Santos M, Díaz-Talavera A, Rubio Á, González P, Hernando B, Bechmann N, Dona M, Calatayud M, Guadalix S, Álvarez-Escolá C, Regojo RM, Aller J, Del Olmo-Garcia MI, López-Fernández A, Fliedner SMJ, Rapizzi E, Fassnacht M, Beuschlein F, Quinkler M, Toledo RA, Mannelli M, Timmers HJ, Eisenhofer G, Rodríguez-Perales S, Domínguez O, Macintyre G, Currás-Freixes M, Rodríguez-Antona C, Cascón A, Leandro-García LJ, Montero-Conde C, Roncador G, García-García JF, Pacak K, Al-Shahrour F, Robledo M. Calsina B, et al. Nat Commun. 2023 Feb 28;14(1):1122. doi: 10.1038/s41467-023-36769-6. Nat Commun. 2023. PMID: 36854674 Free PMC article.
Minimally invasive versus open adrenalectomy for adrenocortical carcinoma: the keys surgical factors influencing the outcomes-a collective overview.
Giordano A, Feroci F, Podda M, Botteri E, Ortenzi M, Montori G, Guerrieri M, Vettoretto N, Agresta F, Bergamini C. Giordano A, et al. Langenbecks Arch Surg. 2023 Jun 30;408(1):256. doi: 10.1007/s00423-023-02997-z. Langenbecks Arch Surg. 2023. PMID: 37386332 Review.
Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma.
Schloetelburg W, Hartrampf PE, Kosmala A, Serfling SE, Dreher N, Schirbel A, Fassnacht M, Buck AK, Werner RA, Hahner S. Schloetelburg W, et al. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3643-3650. doi: 10.1007/s00259-024-06800-z. Epub 2024 Jun 19. Eur J Nucl Med Mol Imaging. 2024. PMID: 38896128 Free PMC article.
The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.
Mizdrak M, Tičinović Kurir T, Božić J. Mizdrak M, et al. Biomedicines. 2021 Feb 10;9(2):174. doi: 10.3390/biomedicines9020174. Biomedicines. 2021. PMID: 33578890 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Affiliations

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Authors

Affiliations

Erratum in

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical